Clinical trial NCT03615677: Efficacy and Safety of LXI-15028 Comparing With Esomeprazole in the Treatment of Erosive Esophagitis
Official title: A Multi-center, Randomized, Double-blind, Parallel-group, Active-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of LXI-15028 Comparing With Esomeprazole in the Treatment of Erosive Esophagitis in Chinese Patients for up to 8 Weeks
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Erosive Esophagitis (EE)
Lead sponsor: Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2018-08-06
Enrollment: 261
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a multi-center, randomized, double-blind, parallel-group, active controlled Phase III clinical study to evaluate the efficacy and safety of LXI-15028 50 mg comparing with esomeprazole 40 mg after the treatment of erosive esophagitis in Chinese patients for up to 8 weeks.

Screening-eligible subjects will be randomized into LXI-15028 50mg treatment group or esomeprazole 40mg treatment group at Visit 2 (Day 0) stratified by LA grade (A or B/C/D) at baseline according to the ratio of 1:1 and receive study treatment continuously for 4 or 8 weeks. They will start to take the investigational products from the following morning (Day 1) of Visit 2, and start to complete the subject's diary from the day of study treatment initiation. After 4 weeks of study treatment (treatment period 1), subjects will return to the study site and complete Visit 3. For the subjects who achieve endoscopic healing at Visit 3, the study treatment will be terminated. The subjects who fail to achieve endoscopic healing at Visit 3 will receive newly dispensed investigational product after completing the fasting examinations at Visit 3, and continue another 4 weeks of study treatment (treatment period 2) and complete Visit 4. All the subjects will be followed up by phone (Visit 5) at Day 28±3 after the last dose of investigational products.


Eligibility criteria: Inclusion Criteria:

* 1) Subject who volunteers to sign the written informed consent form approved by the independent ethics committee and agrees to participate in this study prior to the initiation of any study procedures.

  2) Subject who is able to understand and comply with the protocol requirements and agrees to participate in all the study visits.

  3) Male or female subjects with age ≥ 18 years. 4) Having experienced heartburn and regurgitation within 7 days prior to screening, with the frequency and severity in symptom assessment meeting at least one of the following items:
* Mild heartburn for at least 2 days, with regurgitation;
* Mild regurgitation for at least 2 days, with heartburn;
* Moderate or more severe heartburn for at least 1 day, with regurgitation;
* Moderate or more severe regurgitation for at least 1 day, with heartburn. (Note: To be determined by using the RDQ \[item a, b, e, f\] completed by subject.) 5) Subject who is diagnosed as Los Angeles (LA) grade A to D erosive esophagitis through upper gastrointestinal endoscopy within 14 days prior to the initiation of study treatment. (Note: The target of enrollment is to ensure the number of subjects with LA grade A does not exceed 60% of the total number of subject enrolled)

Exclusion Criteria:

* 1) Subject who had participated in this study previously, or had participated in other P-CAB drug clinical studies.

  2) Participation in other clinical study within 3 months prior to screening, except for the two following circumstances:
* The study which the subject is participating or participated in is a non-interventional study (e.g. observational study or questionnaire survey) and is judged by investigators to have no interference with the efficacy and safety evaluation in the present study;
* Subject had signed the informed consent form and participated in another study (NC821603) sponsored by this sponsor in the same study site, but had been withdrawn from that study prior to the start of any treatment.

  3) Subjects who participate in the plan or conduction of this study (e.g., staff of the sponsor or study site).

  4) Subject who is known to be allergic to the active ingredient or excipient of the investigational product (including esomeprazole).

  5) Subject who is unable to undertake an upper gastrointestinal endoscopy. 6) Subject who is unable to complete the subject's diary by oneself. 7) Subject who has history of manic-depression, anxiety disorder, panic disorder, somatoform disorder, personality disorder or other mental disorder.

  8) Subject who has symptoms such as odynophagia, serious dysphagia, bleeding, decreased body weight, anemia or hematochezia that represent "warning" to presume gastrointestinal malignant disease, unless the possibility of the malignant disease is excluded through an endoscopy.

  9) Subject who is diagnosed as achalasia of the cardia, secondary esophageal motility disorder, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), Zollinger-Ellison syndrome or eosinophilic esophagitis.

  10) Subject with history of digestive tract surgery, except for simple fenestration, appendectomy, cholecystectomy or endoscopic resection of benign tumor. 11) Subject who plans to be hospitalized for receiving selective surgery during the study.

  12) Subject with non-reflux-related esophageal stenosis, hiatus hernia, gastroesophageal varices, active peptic ulcer, gastric bleeding or malignant tumor that is found in upper gastrointestinal endoscopy.

  13) Subject with uncontrolled and unstable hepatic, renal, cardiovascular, respiratory, endocrine or central nervous system disease as judged by investigators.

  14) Subject with history of chronic alcohol consumption (more than 14 cups per week, each cup corresponds to 360 mL beer or 150 mL wine or 45 mL liquor) or drug abuse within 5 years prior to screening.

  15) Use of any PPI, P-CAB or other drugs related to the treatment of GERD (including H2-receptor antagonist, prostaglandin or mucosal protective agent), or any other antiemetic, emetic drugs within two weeks prior to the initiation of study treatment.

  16) Subject who needs non-steroidal anti-inflammatory drugs (NSAIDs) during the study, unless the subject had started to use low dose aspirin (≤ 100 mg/day) prior to screening.

  17) Use of potent-to-moderate cytochrome metabolism enzyme CYP3A4 inhibitor or inducer within 4 weeks prior to study treatment, including but not limited to the following drugs:
* CYP3A4 inhibitors: Ketoconazole, Indinavir, Saquinovir, Atazanavir, Amprenavir, Fosamprenavir, Nefazodone, Itraconazole, Telithromycin, Fluconazole, Troleandomycin, Cimetidine, Aprepitant, Fluvoxamine, Amiodarone, Ritonavir, Erythromycin, Clarithromycin, and Diltiazem;
* CYP3A4 inducers: Barbiturate, Phenytoin, Rifampin, St John's wort, Carbamazepine, Dexamethasone, Rifabutin, and Phenobarbital etc.; 18) Subject currently using antipsychotic drug, antidepressant agent or anti-anxiety agent.

  19) Any of the following laboratory abnormalities at screening:
* AST ≥ 2 x upper limit of normal (ULN);
* ALT ≥ 2 x ULN;
* ALP ≥ 2 x ULN;
* γ-GT ≥ 2 x ULN;
* Total bilirubin ≥ 2 x ULN;
* BUN (or urea) ≥ 1.5 x ULN;
* Creatinine ≥ 1.5 x ULN 20) Subject with clinically significant abnormality in ECG at screening, including serious arrhythmia, multifocal premature ventricular contraction (PVC), second degree or above atrioventricular block, prolonged QT interval (QTc ≥ 450 ms for male, QTc ≥ 470 ms for female).

  21) Current infection of human immune deficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) confirmed by tests.

Primary outcomes:
measure: Cumulative endoscopic healing rate
timeFrame: 4 or 8 weeks after receiving oral doses
Secondary outcomes:
measure: Endoscopic healing rate at Week 4
timeFrame: 4 week after receiving oral doses
measure: Change of Reflux Disease Questionnaire (RDQ) score for main symptoms
timeFrame: 4 or 8 weeks after receiving oral doses
measure: Change of Reflux Disease Questionnaire (RDQ) score for subcategory
timeFrame: 4 or 8 weeks after receiving oral doses
measure: Symptom assessment based on subject diary
timeFrame: 4 or 8 weeks after receiving oral doses
measure: Change of Gastro Esophageal Reflux Disease-Health Related Quality of Life (GERD-HRQL) score
timeFrame: 4 or 8 weeks after receiving oral doses
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Shanghai First People's Hospital
state: Shanghai
Study officials:
affiliation: Changhai Hospital
name: Zhaoshen Li, Doctor
role: PRINCIPAL_INVESTIGATOR
References: